TGFB1 and hematopoietic and lymphoid cell neoplasm: Alongside the anti-TGF-β neutralizing antibodies or engineered NK cells to knock-down TGF-β receptor expression, other strategies such as small molecule receptor kinase inhibitors can be implemented for CAR-NK cell therapy in hematological cancers (238, 239).